August 18
Building the First New Therapeutic Approach to Periodontitis in Decades
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Curtin Health Innovation Research Institute (CHIRI) is dedicated to developing new treatments for diseases that more commonly occur with older age.
ViewOur vision is to perform world-class medical research that focuses on the molecular basis of health and disease. The specific areas of our research include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity.
ViewCommitted to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreSix Australian startup health innovators awarded $13.5 million through CUREator+ to accelerate breakthrough medical therapies and technologies.
Read moreKraken Coding: from hospital pharmacy to health-tech founder on a mission to help clinicians make faster, safer decisions
Read more